Effect of thalidomide on gastrointestinal toxic effects of irinotecan

Lancet

Volumn 356, Issue 9229, 2000, Pages 566-567

  Govindarajan, Rangaswamy ^a   Heaton, Keith M ^a   Broadwater, J Ralph ^a   Zeitlin, Andrew ^b   Lang, Nicholas P ^a   Hauer Jensen, Martin ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; IRINOTECAN; THALIDOMIDE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; METASTASIS; NAUSEA; PRIORITY JOURNAL; UNITED STATES; VOMITING;

EID: 0034641526     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02586-1     Document Type: Article

References (5)

1. D Cunningham S Pyrhonen R James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418
2. JR Hecht Gastrointestinal toxicity of irinotecan Oncology 12 1998 72 78
3. JB Marriott G Muller A Dalgleish Thalidomide as an emerging immunotherapeutic agent Immunol Today 20 1999 538 540
4. M D'Amato M Loughnan E Flynn J Folkman Thalidomide is an inhibitor of angiogenesis Proc Nat Academy Sci 91 1994 4082 4085
5. + secretion in human distal colon driven by prostaglandin E2 Am J Physiol 271 1996 669 674